News

The American Journal of Managed Care15d
GLP-1 RAs, SGLT2 Inhibitors Associated With Reduced MACE, HHF in Patients With Diabetes
GLP-1 RAs and SGLT2 inhibitors significantly reduce cardiovascular events and heart failure risk in older adults with type 2 diabetes compared to DPP-4 inhibitors. The study utilized health ...
Medscape15d
Infections Higher With JAK Inhibitors in Atopic Dermatitis Study
Janus kinase (JAK) inhibitors were associated with more infections, particularly herpes infections, in patients with atopic dermatitis (AD) compared with biologics, in a cohort study. A ...
clinicaltrialsarena15d
AAN 2025: Sanofi’s tolebrutinib likely to be first BTK inhibitor for the treatment of MS
The presentation highlighted tolebrutinib’s potential as the first Bruton’s tyrosine kinase (BTK) inhibitor to receive regulatory approval for the treatment of progressive MS. During the Clinical ...
verywellhealth15d
CGRP Inhibitors for Migraine Treatment
Calcitonin gene-related peptide (CGRP) inhibitors are now considered a first-line treatment used to treat and prevent migraines. There are two types of CGRP medications: monoclonal antibodies and ...
Yahoo Finance15d
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
Salt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the ...
Healio16d
Daily oral PCSK9 inhibitor cut LDL cholesterol by 50% over 12 weeks
A once-daily oral PCSK9 inhibitor reduced LDL in patients with hypercholesterolemia. Safety and tolerability profiles were favorable, according to investigators. CHICAGO — In a phase 2b study ...
The American Journal of Managed Care16d
Meta-Analysis Finds SGLT2 Inhibitors Boost Hemoglobin, Hematocrit in CKD
SGLT2 inhibitors significantly improve hemoglobin and hematocrit levels in CKD patients, enhancing anemia management. The KDIGO 2024 guideline endorses SGLT2 inhibitors for CKD patients ...
dermatologyadvisor17d
JAK Inhibitors Often Used to Treat JDM, Despite Data Gaps and Access Barriers
Survey results revealed that 66% of pediatric rheumatology providers reported prescribing off-label Janus kinase inhibitors to treat juvenile dermatomyositis. Janus kinase (JAK) inhibitors are ...
Targeted Oncology17d
Checkpoint Inhibitors Deliver Longer OS in PPP2R1A-Mutated Endometrial Cancer vs Wild-Type Disease
Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed inactivating PPP2R1A mutations vs patients with wild-type PPP2R1A. “Further ...
gut.bmj19d
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
Palbociclib, a well-tolerated and selective CDK4/6 inhibitor, has shown promising results in the treatment of retinoblastoma (RB1)-positive breast cancer. RB1 is rarely mutated in HCC, suggesting that ...
Healthline22d
What Are SGLT2 Inhibitors, and How Do They Work?
SGLT2 inhibitors are medications designed to help manage blood sugar in people living with type 2 diabetes. Learn more about the different types, as well as the benefits and side effects.